articleTop 1% cited
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Breast Cancer Research and Treatment · 2010 · Vol. 128(2) · pp. 347–356
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchPeptidase Inhibition and AnalysisTrastuzumabLapatinibTrastuzumab emtansineAntibody-dependent cell-mediated cytotoxicityPertuzumabMedicineBreast cancerMetastatic breast cancerCancer researchAntibody-drug conjugate
MeSH terms
TrastuzumabLapatinibAdo-Trastuzumab EmtansineAnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityImmunotoxinsBreast NeoplasmsCell SurvivalFemaleHumansMaytansineMice, NudeMice, TransgenicQuinazolines
Citations
528
FWCI
14.08
field-weighted impact
References
34
Percentile
99%
vs. same field & year
Citations per year
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Nature Reviews Drug Discovery · 2017 · 2,087 citations
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Clinical Cancer Research · 2016 · 1,057 citations
References
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Cancer Research · 2008 · 1,659 citations
The Hallmarks of Cancer
Cell · 2000 · 28,385 citations
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Analytical Biochemistry · 1980 · 8,490 citations
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · 1,856 citations
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Nature Medicine · 2000 · 2,723 citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.